Biotechnological innovations, both in industry and academia, have resulted in scores of lifesaving products and methods. These advances, however, require enormous monetary investments by biotechnology and pharmaceutical companies, which the companies will make only if there is a possibility of return on the investment – a possibility provided by patent protection.
In the last few years, United States Supreme Court has set a new course. The holdings in Mayo, Myriad, and Alice severely limit the scope of patent-eligible subject matter in ways that have severely undercut the biotechnology and biopharma industries. This presentation explores these cases and reviews the most recent reactions in lower courts and in the USPTO. More importantly, the presentation provides strategies and tactics for ways stakeholders in the biotechnology and biopharma industries can continue to protect innovations under the new regime.
CLE credit is not available for viewing this recording.
November 4, 2015
Although we would like to hear from you, we cannot represent you until we know that doing so will not create a conflict of interest. Also, we cannot treat unsolicited information as confidential. Accordingly, please do not send us any information about any matter that may involve you until you receive a written statement from us that we represent you (an ‘engagement letter’).
By clicking the ‘ACCEPT’ button, you agree that we may review any information you transmit to us. You recognize that our review of your information, even if you submitted it in a good faith effort to retain us, and, further, even if you consider it confidential, does not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you. Please click the ‘ACCEPT’ button if you understand and accept the foregoing statement and wish to proceed.